Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE & FAST Trial
NCT06549842Completed
- Sponsor
- Regional Hospital of Scranton
- Start
- Aug 2024
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Randomised, open-label trial of heparin in Radial artery occlusion (RAO) and hemorrhage (2 arms), sponsored by Regional Hospital of Scranton. Primary endpoints: Rebound bleeding at 24 hours, Radial artery occlusion at 24 hours and 1 more. Started Aug 2024; status: completed.
02
Drugs
heparin
03
Conditions
Radial artery occlusion (RAO)hemorrhage
Beyond the preview
Go deeper on NCT06549842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549842.